CAR-T Study – A Milestone in Autoimmune Therapy
We are proud to have successfully treated the first SLE patient in Australia with a cutting-edge CAR-T cell therapy. Although this study is now closed to recruitment, it represents a major advancement in the treatment of autoimmune conditions.
Stay tuned for future CAR-T trial options for autoimmune diseases in 2027
Ongoing Research Opportunity
Study ID: ASSURO
Sponsor: AstraZeneca
Investigational Drug: surovatamig
Age: 18-65 years (or age of consent)
Eligibility: Diagnosed with rheumatoid arthritis (RA) and have not responded to (or could not tolerate) 2 or more treatments; OR Diagnosed with systemic lupus erythematosus (SLE) and have not responded to (or could not tolerate) 3 or more treatments
More information: RheumatologyClinicalTrials@monashhealth.org
Recruiting Now- ELOWEN
Researchers conducting the ELOWEN Study are exploring whether an investigational medicine taken by mouth can help safely treat people with lupus who have skin rashes or sores, regardless of whether their other organs or joints are affected.
The study is seeking adults who:
- Are 18 to 75 years
- Have had lupus for at least 6 months
- Have skin symptoms related to lupus
Other criteria also apply. You will receive more information if you decide to contact the study team. Participants in this study will be randomly (by chance) assigned to either investigational medicine or placebo.
Participation in the study is entirely voluntary. By contacting the team for more information, you are not obligated to participate in the study in any way.
More information: RheumatologyClinicalTrials@monashhealth.org
New Phase III Sjögren’s Study – Coming in 2027
–details to come
